

CMBI Credit Commentary

Fixed Income Daily Market Update 固定收益部市场日报

- *AT1 bounced back to 0.1-0.3pt higher this morning. VNKRL 27-29 edged 0.7-0.8pt higher. SOFTBK 31-65s were 0.4-0.8pt higher. VLLPM 29 dropped another 1.5pts. ACPM 4.85 Perp was 0.9pt lower.*
- *BSFR: FY25 net income up 18% yoy to SAR5.3bn on stronger operating income and lower net ECL. See below.*
- *DALWAN: Dalian Wanda reduced sole offshore loan outstanding to USD150mn from Wanda Hotel Management sale proceeds. DALWAN 12.75 02/05/28 was 0.1pt higher this morning.*

❖ Trading desk comments 交易台市场观点

Last Friday, the new MIZUHO Float 32 and MIZUHO 32-37 tightened 2-3bps from ROs. HYUELEs squeezed another 3-4bps tighter. S&P upgraded SK Hynix by one notch to BBB+ from BBB on expected strong operating performance over the next 12 months driven by demand growth in high-bandwidth memory (HBM) and conventional memory. In HK, FAEACO 12.814 Perp/SUNHKC 26/LASUDE 26/BTSDF 28 edged 0.1-0.2pt higher. In Chinese properties, LNGFOR 27-32 were unchanged to 0.6pt lower. VNKRL 27-29 closed 0.1-0.3pt lower. FUTLAN 28/FTLNHD 26-27 were 0.1pt lower to 0.1pt higher. In SE Asian space, GLPSPs dropped another 0.8-1.5pts, and GLPCHI 29 was 0.7pt lower. See our comments [last Friday](#) on downstream liquidity support from GLPSP to GLPCHI through a parent-backed tender offer. VLLPM 27-29 leaked 2.0-2.2pts. On the other hand, ACPM 3.9 Perp was 0.6pt higher. Media reported that Ayala Corp's subsidiary Ayala Land is considering bidding for two Philippines assets valued at a total of PHP40.5bn (cUSD688mn). SMCGL Perps were unchanged to 0.4pt higher. In Indonesian space, MEDCIJs/INDYIJ were 0.1-0.5pt lower, except for MEDCIJ 26 edged 0.1pt higher. Moody's changed the outlook of Indonesia to negative from stable on reduced predictability in policymaking and affirmed its Baa2 ratings. VEDLN 28-33s traded up to 0.5pt lower. IHFLIN 27-30s closed 0.1-0.3pt lower. In the Middle East, BSFRs were unchanged to 0.1pt lower. See comments on its FY25 results below. Long-end KSAs were 0.1pt lower to 0.2pt higher. Yankee AT1s leaked another 0.1pt despite some PB and AM buying from Asia. LGFVs remained firm as higher-yielding papers continued to compress tighter.

Glenn Ko, CFA 高志和
 (852) 3657 6235
 glennko@cmbi.com.hk

Cyrena Ng, CPA 吴倩莹
 (852) 3900 0801
 cyrenang@cmbi.com.hk

Yujing Zhang 张钰婧
 (852) 3900 0830
 zhangyujing@cmbi.com.hk

❖ Last Trading Day's Top Movers

Top Performers	Price	Change	Top Underperformers	Price	Change
KZOKZ 3 1/2 04/14/33	90.6	0.8	TTMTIN 4.35 06/09/26	97.6	-2.3
CIFIHG 0 06/30/27	7.5	0.7	VLLPM 7 1/4 07/20/27	56.6	-2.2
GARUDA 6 1/2 12/28/31	92.5	0.7	VLLPM 9 3/8 07/29/29	44.7	-2.0
PTTTB 5 7/8 08/03/35	105.8	0.6	GLPSP 4.6 PERP	67.2	-1.5
ACPM 3.9 PERP	67.1	0.6	GLPSP 4 1/2 PERP	71.1	-1.4

❖ Marco News Recap 宏观新闻回顾

Macro – &P (+1.97%), Dow (+2.47%) and Nasdaq (+2.18%) were higher on last Friday. 2/5/10 year UST yield was higher on last Friday. 2/5/10/30 year yield was at 3.50%/3.76%/4.22%/4.85%.

❖ Desk Analyst Comments 分析员市场观点

➤ **BSFR: FY25 net income up 18% yoy to SAR5.3bn on stronger operating income and lower net ECL**

We maintain buy on BSFR 6.375 Perp and BSFR 5.761 09/03/35, we view they offer more appealing risk-return profiles compared with those of its peers. These are the first USD AT1 and T2 issued by Banque Saudi Fransi (BSF). We consider the likelihood of its AT1 and T2 to be called on first call date is high given BSF's large capital buffer even though SAMA proactively raised CET1 requirements for 25bps in Jan'26 and will raise another 50bps in May'26 for D-SIBs in view of interest rate volatility and fast loan growth. We take some comfort on BSF's call record in Nov'25 when it redeemed BSFR Float Perp of SAR5bn on the first call date, which was the first AT1 instrument issued by BSF back in 2020. The redemption was partly funded by issuance of BSFR 6.4 Perp of SAR2.5bn. See below for our AT1 and T2 picks within Middle East space.

Table 1: Our Middle East AT1 and T2 picks

Security name	Amt o/s (USDmn)	Basel III	Ask px	YTC	Mod dur	First call	First coupon reset	Issue rating (M/S/F)	Issuer rating (M/S/F)
BSFR 6.375 Perp	650	AT1	100.8	6.2%	4.0	11/07/2030	05/07/2031	Unrated	A1/A-/A-
BSFR 5.761 09/03/35	1000	T2	100.0	5.8%	3.9	09/03/2030	09/03/2030	-/-/BBB	A1/A-/A-
FABUH 6.32 04/04/34	1,000	T2	104.1	4.7%	2.4	10/04/2028	04/04/2029	-/-/A	Aa3/AA-/AA-
FABUH 5.804 01/16/35	750	T2	103.0	4.8%	3.1	07/16/2029	01/16/2030	-/-/A	Aa3/AA-/AA-

Source: Bloomberg.

BSF's FY25 operating income rose 9% yoy to SAR10.5bn, driven by a 10% yoy increase in net special commission income to SAR8.9bn, supported by 5% yoy loan growth. NIM was stable at 3.04% in FY25 and FY24, the lower cost of deposit and reduced hedging costs were offset by a decline in interest yields following rate cuts. Saudi Arabia cut interest rate 3 times with 25bps each in Sep, Oct and Dec'25. Net fee and commission income declined 2% yoy lower to SAR956mn due to higher fee and commission expenses. FY25 net ECL fell 15% yoy, reflecting higher recoveries and lower commercial ECL, partly offset by higher consumer ECL. The gross ECL was SAR1.4bn, 7% yoy higher than FY24. As a result, FY25 net income rose 18% yoy to SAR5.3bn. ROE improved to 10.7% in FY25 from 10.3% in FY24, slightly below internal guidance of 11-12%, reflecting higher operating expenses. For FY26, BSF guided a stable NIM of c3% and an improvement in ROE to 12-13%, driven by higher operating income and disciplined cost management.

Asset quality was broadly stable as of Dec'25, with mild increase in NPL and decrease in NPL coverage ratio compared to that of Dec'24. The NPL ratio rose to 0.97% from 0.93%, driven by both commercial and consumer portfolio, while the NPL coverage ratio dropped to 178% from 182%. That said, BSF's capital remained ample. The CET 1 ratio rose to 16.2% as of Dec'25 from 15.8% as of Dec'24, comfortably above the regulatory minimum requirement of 7.5%. BSF guided CET1 ratio to remain stable in FY26 at >15%. Liquidity also strengthened, with liquidity coverage ratio increased to 194% as of Dec'25 from 162% as of Dec'24.

➤ **Offshore Asia New Issues (Priced)**

Issuer/Guarantor	Size (USD mn)	Tenor	Coupon	Priced	Issue Rating (M/S/F)
No Offshore Asia New Issues Priced Today					

➤ **Offshore Asia New Issues (Pipeline)**

Issuer/Guarantor	Currency	Size (USD mn)	Tenor	Pricing	Issue Rating (M/S/F)
No Offshore Asia New Issues Pipeline Today					

➤ **News and market color**

- Regarding onshore primary issuances, there were 126 credit bonds issued yesterday with an amount of RMB110bn. As for Month-to-date, 608 credit bonds were issued with a total amount of RMB521bn raised, representing a 6625.6% yoy increase
- **[BHARTI]** Bharti Airtel seeking recalculation of USD4.4bn in AGR dues with India's government, not deferment
- **[BIOLIN]** Fitch revised the outlook of Biocon Biologics to positive from stable, affirmed BB- rating
- **[DALWAN]** Dalian Wanda reduced sole offshore loan outstanding to USD150mn from Wanda Hotel Management sale proceeds
- **[HNMNWP]** Hanuman Wind Power postponed USD bond deal
- **[INCLEN/INGPHL/RNW/RPVIN]** ReNew Global project SPV obtained USD50mn debt funding from DEG. Total project cost is USD615.6mn with 20:80 equity and senior debt. Senior debt of USD 492.5mn to be split between ADB, DFI's facility
- **[LGCHM]** LG Chem battery arm to buy out Stellantis, gain full control of Canadian JV
- **[TYANLI]** Tongyang Life Insurance FY25 sales rose 2.1% yoy KRW3.6tn (cUSD2.4bn)
- **[ZHHFGR]** Zhuhai Huafa Properties forecasted RMB7-9bn net loss for FY25, mainly to increase in interest expenses, loss from asset disposal and provision for asset impairment

Fixed Income Department

Tel: 852 3657 6235/ 852 3900 0801

fis@cmbi.com.hk

Author Certification

CMBIGM or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months

The author who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the author covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that author in this report.

Besides, the author confirms that neither the author nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

Disclaimer:

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide

this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.